May 25, 2022— Federal appeals courts are considering legal challenges to the government’s authority to require drug companies to restore 340B drug pricing program discounts on drugs dispensed at community and specialty pharmacies. In a series of legal briefs filed with two of the courts, five national hospital associations and 25 state attorneys general urged the courts to … [Read more...]
With 340B Pricing Restrictions, Hospitals Are Facing Double the Trouble
May 18, 2022— Safety-net hospitals participating in the 340B drug pricing program are reporting that the negative effects of restrictions imposed by pharmaceutical companies on access to drug price discounts are rapidly rising. A new survey of more than 500 hospitals participating in 340B finds that the financial losses from these restrictions more than doubled in three short … [Read more...]
340B Community Pharmacy Legal Battle Moves to Next Stage
April 18, 2022— A nearly two-year dispute between hospitals participating in the 340B drug discount program and a group of drug companies pulling back from their 340B commitments has fully entered a new phase of legal wrangling. Over the coming months, three federal appeals courts will review lower court decisions that came to differing conclusions on what federal law says … [Read more...]
Drugmakers Cutting 340B Discounts Reported Record Revenues Last Year
March 10, 2022– The 14 drug companies that have imposed or announced restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in more than a half-trillion dollars in revenues in 2021. The banner year for the drugmakers occurred as hospitals reported increasing losses of 340B savings from the cuts. Last month, most drug companies … [Read more...]
GlaxoSmithKline Policy Threatens Asthma Care
Feb. 16, 2022– Just days after President Biden spoke out in support of the 340B drug pricing program, drug giant GlaxoSmithKline (GSK) announced it will begin withholding 340B discounts starting in April for most safety-net hospitals. That action will bring the number of drug companies violating the 340B law to 14. In 2021, GSK reported more than $45 billion in global sales, … [Read more...]
Survey Shows the Loss of 340B Savings is a Big and Growing Problem for Safety-Net Hospitals
Feb. 2, 2022– More than a dozen pharmaceutical companies have pulled back on 340B drug pricing program discounts that federal law requires them to offer safety-net hospitals that care for the nation’s patients who are in the most need. New survey data demonstrate how these drugmaker actions already have taken major bites out of the resources that hospitals rely on to fulfill … [Read more...]
More Court Battles Ahead for 340B in 2022
Jan. 12, 2022– The dispute between safety-net hospitals and a growing group of drug companies over community-based pharmacies in the 340B drug pricing program is heading into a new phase of legal wrangling that ensures this fight will remain a dominant issue in the 340B world for months to come. As 2021 ended, two industry giants – Amgen and AbbVie – joined the group of … [Read more...]